Equity Profile

INDV

Indivior Pharmaceuticals, Inc.

Health CarePharmaceuticals$4.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative medicines for the treatment of addiction and mental health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge how well Indivior is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the demand for Indivior's products and its market position, especially in the competitive pharmaceutical sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative medicines for the treatment of addiction and mental health conditions. With a market cap of $5 billion, its work is particularly relevant as society increasingly addresses issues related to substance use disorders.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q1-2026, Indivior reported an EPS of $0.96, significantly exceeding expectations of $0.64, marking a 50.71% surprise. The stock reacted positively, gaining 7.70% the next day.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving patient access to its medications.
Plans to invest in research and development for new treatments.

Expectations

Wall Street Expectations

Overall, expectations for Indivior's upcoming earnings are cautious, given the lack of analyst estimates and management guidance. Investors are keen to see if the company can maintain its positive momentum.

Bull Case

If Indivior continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, leading to further stock price appreciation.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong track record of beating EPS estimates, this figure will be crucial in determining market sentiment and stock performance.

How is Indivior addressing market competition and product demand?

Understanding the company's strategy in a competitive landscape will help investors assess its future growth potential and market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Indivior's ability to leverage its recent product innovations, which could drive stronger-than-expected demand.

Supporting Evidence

Indivior has consistently beaten EPS estimates, suggesting operational strength.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Management's previous commitments to expanding product access could translate into better-than-expected revenue.

Key Risk

If the EPS comes in below $0.80, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Indivior's ability to sustain its growth and profitability amidst increasing competition and market challenges.

Bull Confirmed If

An EPS of $1.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.80 would confirm the bear case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±20.61%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by an average of 9.86%, confirming strong operational performance.

In-Line / Cautious

A cautious inline report could lead to muted market reactions, as investors weigh the implications of management commentary.

Miss

Should the company miss expectations, history indicates a potential downside move, averaging around 9.86%, which could raise concerns about its growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on regulatory approvals for existing or new treatments.
3Insights into market competition and how Indivior plans to maintain its market position.
4Management's outlook on future earnings and growth strategies.
5Responses to analyst questions regarding operational challenges and market dynamics.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative medicines for the treatment of addiction and mental health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge how well Indivior is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the demand for Indivior's products and its market position, especially in the competitive pharmaceutical sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q1-2026, Indivior reported an EPS of $0.96, significantly exceeding expectations of $0.64, marking a 50.71% surprise. The stock reacted positively, gaining 7.70% the next day.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving patient access to its medications.
Plans to invest in research and development for new treatments.

Expectations

Wall Street Expectations

Bull Case

If Indivior continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, leading to further stock price appreciation.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong track record of beating EPS estimates, this figure will be crucial in determining market sentiment and stock performance.

How is Indivior addressing market competition and product demand?

Understanding the company's strategy in a competitive landscape will help investors assess its future growth potential and market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Indivior's ability to leverage its recent product innovations, which could drive stronger-than-expected demand.

Supporting Evidence

Indivior has consistently beaten EPS estimates, suggesting operational strength.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Management's previous commitments to expanding product access could translate into better-than-expected revenue.

Key Risk

If the EPS comes in below $0.80, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Indivior's ability to sustain its growth and profitability amidst increasing competition and market challenges.

Bull Confirmed If

An EPS of $1.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.80 would confirm the bear case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±20.61%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by an average of 9.86%, confirming strong operational performance.

In-Line / Cautious

A cautious inline report could lead to muted market reactions, as investors weigh the implications of management commentary.

Miss

Should the company miss expectations, history indicates a potential downside move, averaging around 9.86%, which could raise concerns about its growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on regulatory approvals for existing or new treatments.
3Insights into market competition and how Indivior plans to maintain its market position.
4Management's outlook on future earnings and growth strategies.
5Responses to analyst questions regarding operational challenges and market dynamics.